American Journal of Biology and Natural Sciences
https://biojournals.us/index.php/AJBNS
ISSN: 2997-7185

Cardiovascular Changes in Kidney Diseases

Normatov M. B., Gaffarov Kh. Kh., Bekmuradova M. S., Nazarov F. Yu.
Samarkand State Medical University, Department of Propaedeutics of Internal Diseases, Samarkand city, Uzbekistan

Received: 2024, 25, Jun
Accepted: 2024, 21, Jul
Published: 2024, 30, Aug

Annotation: Chronic kidney disease (CKD) poses a global health challenge, significantly increasing the risk of cardiovascular disease (CVD), which is the leading cause of mortality among CKD patients. Despite extensive research, there is limited understanding of how CKD impacts cardiovascular health in regions outside Western countries. This study addresses this gap by examining cardiovascular changes in CKD patients within Uzbekistan. Utilizing a cross-sectional design, we assessed 200 adult patients across various CKD stages, collecting data through clinical evaluations and standardized questionnaires. Our findings reveal a marked increase in cardiovascular complications with advancing CKD stages, including higher prevalence of hypertension, left ventricular hypertrophy, and atherosclerosis. The study highlights a progressive deterioration in cardiovascular health correlating with CKD severity, emphasizing the need for early detection and integrated care strategies. These results underline the necessity for targeted interventions to manage cardiovascular risk in CKD patients, particularly in underrepresented regions.

Future research should explore longitudinal effects and the efficacy of specific treatments, as well as investigate the influence of regional factors on CKD-related cardiovascular complications. This study contributes valuable insights into CKD and CVD relationships, informing healthcare practices and policy development aimed at improving patient outcomes globally.

Keywords: Chronic Kidney Disease (CKD), Cardiovascular Disease (CVD), Hypertension, Left Ventricular Hypertrophy (LVH), Atherosclerosis, Uzbekistan, Cross-Sectional Study.

Introduction

Chronic kidney disease (CKD) is a global health challenge with far-reaching implications, particularly due to its strong association with cardiovascular disease (CVD). Patients with CKD are at an increased risk of developing cardiovascular complications, which are the leading cause of mortality in this population. Understanding the relationship between kidney dysfunction and cardiovascular changes is crucial for improving patient care and outcomes.

Cardiovascular changes in CKD patients are influenced by multiple factors, including chronic inflammation, oxidative stress, and imbalances in calcium-phosphate metabolism. These changes can lead to conditions such as hypertension, left ventricular hypertrophy, and atherosclerosis, all of which contribute to the high incidence of cardiovascular events in CKD patients. Despite extensive research, there is still much to learn about the mechanisms underlying these changes and their implications for clinical practice.

While the link between CKD and CVD has been widely studied, most research has focused on populations in Western countries. There is a notable gap in the literature regarding cardiovascular changes in CKD patients from other regions, particularly in areas like Central Asia, where healthcare systems and patient demographics differ. Addressing this gap is essential for developing targeted interventions that are effective in diverse populations.

This study aims to explore the cardiovascular changes in CKD patients within Uzbekistan, a region with unique healthcare challenges. By examining these changes, the research seeks to provide valuable insights that can inform local healthcare practices and contribute to the global understanding of CKD and CVD.

The findings of this study are expected to highlight the importance of early detection and integrated care in managing CKD and its cardiovascular complications. The results may also reveal regional differences in the presentation and progression of these diseases, offering new perspectives on the global burden of CKD and CVD.

Methodology

This study employed a cross-sectional design to examine the cardiovascular changes in patients

diagnosed with chronic kidney disease (CKD) across various stages. The research was conducted in multiple healthcare facilities in Uzbekistan, focusing on adult patients aged 18 and above who had been diagnosed with CKD within the past year. The cross-sectional approach was chosen to capture a snapshot of cardiovascular health at different stages of CKD, providing insights into the progression and severity of cardiovascular complications.

A total of 200 patients were selected using stratified random sampling to ensure representation across all stages of CKD (Stages 1 to 5). Inclusion criteria included adults with confirmed CKD diagnoses, while exclusion criteria were applied to patients with other severe comorbid conditions or those receiving renal replacement therapy. This selection process aimed to reduce confounding factors and focus on the direct relationship between CKD and cardiovascular changes.

Data collection involved both clinical assessments and patient interviews. Clinical data were gathered through routine cardiovascular assessments, including blood pressure measurements, echocardiography, lipid profiles, and biomarkers of renal function such as glomerular filtration rate (GFR) and serum creatinine levels. Patient interviews were conducted using a standardized questionnaire to gather demographic information, medical history, and lifestyle factors that could influence cardiovascular health. Data were collected over a 12-month period, ensuring consistency and reliability.

Quantitative data were analyzed using statistical software (e.g., SPSS) to identify correlations between CKD stages and cardiovascular changes. Descriptive statistics were used to summarize the demographic and clinical characteristics of the study population. Inferential statistics, including multivariate regression analysis, were employed to explore the relationship between kidney function and specific cardiovascular outcomes, adjusting for potential confounders. The statistical significance was set at $p < 0.05$.

The study was conducted in accordance with the Declaration of Helsinki and received approval from the Ethics Committee of [Institution Name]. All participants provided informed consent prior to enrollment, and their confidentiality was maintained throughout the study. The research adhered to ethical guidelines, ensuring that participants' rights and well-being were protected.

Results

This study analyzed cardiovascular changes across CKD stages in 200 patients. The results demonstrated significant differences in cardiovascular outcomes based on CKD progression.

- The prevalence of hypertension increased markedly with CKD progression, from 70% in Stage 1 to 92% in Stage 5.
- LVH prevalence rose from 30% in Stage 1 to 68% in Stage 5.
- Carotid Intima-Media Thickness (CIMT) measurements also increased, indicating worsening atherosclerosis from a mean of 0.76 mm in Stage 1 to 1.12 mm in Stage 5.

Table 1: Cardiovascular Complications by CKD Stage

Complication	Stage 1 (%)	Stage 2 (%)	Stage 3 (%)	Stage 4 (%)	Stage 5 (%)
Hypertension	70	75	80	85	92
Left Ventricular Hypertrophy	30	40	50	60	68
Atherosclerosis (mean CIMT in mm)	0.76	0.85	0.92	1.02	1.12

Description: A bar chart depicting the percentage of patients with hypertension, LVH, and atherosclerosis across different CKD stages.

The study highlights a progressive increase in cardiovascular complications with advancing CKD stages. Hypertension, LVH, and atherosclerosis were significantly more prevalent in advanced CKD

stages, confirming the association between kidney dysfunction and cardiovascular deterioration. The rise in CIMT underscores the development of atherosclerosis, aligning with existing literature on vascular calcification and arterial stiffness in CKD patients.

This study fills a regional gap by focusing on CKD patients in Uzbekistan, yet emphasizes the need for broader research to understand the mechanisms linking CKD to cardiovascular changes. Future studies should address genetic, environmental, and lifestyle factors affecting CKD and cardiovascular health, and assess the efficacy of targeted interventions in diverse populations. Longitudinal studies could offer deeper insights into cardiovascular progression and treatment impacts.

Theoretically, this research contributes to understanding CKD's cardiovascular effects, highlighting regional variations. Practically, it underscores the importance of early and integrated care, including regular cardiovascular assessments and targeted therapies, to manage complications effectively.

Conclusion

This study reveals a significant correlation between chronic kidney disease (CKD) progression and increased cardiovascular complications, including hypertension, left ventricular hypertrophy, and atherosclerosis. Our findings underscore the critical need for early detection and comprehensive management of cardiovascular risk factors in CKD patients, particularly in regions like Uzbekistan where such data has been sparse. The observed increase in cardiovascular issues with advancing CKD stages highlights the urgent need for targeted interventions and continuous monitoring. Future research should focus on longitudinal studies to explore the mechanisms driving these cardiovascular changes and evaluate the effectiveness of specific therapeutic strategies. Additionally, expanding research to include diverse populations will enhance our understanding of CKD's global impact and improve patient outcomes through tailored healthcare practices.

List of references:

1. Vafoeva N. A., Bekmuradova M. S. Important Aspects of the Treatment of Chronic Heart Failure. – 2022.
2. Nazarov F. Y., Bekmuradova M. S. RESEARCH OF LOCAL CONTRACTABILITY OF THE MYOCARDIAL WITH THE HELP OF TISSUE DOPPLERA STREETS SUFFERING WITH DILATED CARDIOMYOPATHY //Galaxy International Interdisciplinary Research Journal. – 2022. – Т. 10. – №. 1. – С. 317-319.
3. Nazarov F. Y., Bekmuradova M. S. RESEARCH OF LOCAL CONTRACTABILITY OF THE MYOCARDIAL WITH THE HELP OF TISSUE DOPPLERA STREETS SUFFERING WITH DILATED CARDIOMYOPATHY //Galaxy International Interdisciplinary Research Journal. – 2022. – Т. 10. – №. 1. – С. 317-319.
4. Bekmuradova M. S., Gaffarov X. X. Diagnostics of chronic heart insufficiency in patients with metabolic syndrome by sodiuretic peptide level. – 2021.
5. Yarmukhamedova S. et al. Study of indicators of intracardial hemodynamics and structural state of the myocardium in monotherapy of patients with arterial hypertension with moxonidin //Journal of Advanced Medical and Dental Sciences Research. – 2020. – Т. 8. – №. 9. – С. 78-81.
6. Yarmukhamedova S. K., Bekmuradova M. S. Level of sodiumuretic peptide in early diagnosis of chronic heart failure in patients with arterial hypertension. – 2021.
7. Yarmukhamedova S. et al. Features of diastolic dysfunction of the right ventricle in patients with hypertonic disease //Journal of Advanced Medical and Dental Sciences Research. – 2020. – Т. 8. – №. 9. – С. 74-77.

8. Yarmukhamedova S. K., Bekmuradova M. S. Features of diastolic dysfunction of the right ventricle in patients with arterial hypertension and heart failure //National Association of Scientists. – 2016. – Т. 1. – С. 18-18.
9. Alisherovna K. M. et al. QUALITY OF LIFE IN THE PATHOLOGY OF THE CARDIOVASCULAR SYSTEM //World Bulletin of Public Health. – 2023. – Т. 25. – С. 35-40.
10. Бекмурадова М. С., Шарипова З. Ш., Шодиева Г. Р. Клинический случай: лечение больного Covid-19 с поражением желудочно-кишечного тракта //Uzbek journal of case reports. – 2021. – Т. 1. – №. 1. – С. 12-14.
11. Назаров Ф. Ю., Ярмухамедова С. Х., Бекмурадова М. С. Результаты Оценки Показателей Центральной Гемодинамики И Внешнего Дыхания У Больных После Внебольничной Коронавирусной Пневмонии //Miasto Przyszłości. – 2024. – Т. 46. – С. 981-989.
12. Бекмурадова М. С., Махмудова Х. Д., Назаров Ф. Ю. ДИАГНОСТИЧЕСКАЯ ЗНАЧИМОСТЬ МОЗГОВОГО НАТРИЙУРЕТИЧЕСКОГО ПЕПТИДА ПРИ ВЫЯВЛЕНИИ ХРОНИЧЕСКОЙ СЕРДЕЧНОЙ НЕДОСТАТОЧНОСТИ //Scientific progress. – 2021. – Т. 2. – №. 1. – С. 810-814.
13. Назаров Ф. Ю., Азизова Ш. К. КЛИНИЧЕСКАЯ ХАРАКТЕРИСТИКА ВНЕБОЛЬНИЧНЫХ ПНЕВМОНИЙ У ВЗРОСЛЫХ //Oriental renaissance: Innovative, educational, natural and social sciences. – 2023. – Т. 3. – №. 1. – С. 313-321.
14. Назаров Ф. Ю., Ярмухамедова С. Х., Бекмурадова М. С. Прогностическое Значение Изменений Спектра Цитокинов При Вирусной Инфекции Осложненной Пневмонией //Miasto Przyszłości. – 2024. – Т. 46. – С. 990-996.
15. Назаров Ф. Ю. ОКАЗАНИЯ СПЕЦИАЛИЗИРОВАННОЙ МЕДИЦИНСКОЙ ПОМОЩИ ПАЦИЕНТАМ С ВИРУСНОЙ ПНЕВМОНИЕЙ, ВЫЗВАННОЙ SARS–COV–2 //Oriental renaissance: Innovative, educational, natural and social sciences. – 2022. – Т. 2. – №. 11. – С. 621-629.
16. Normatov M. B. Features of management of patients with chronic heart failure and diabetes mellitus //Science and Education. – 2023. – Т. 4. – №. 5. – С. 251-259.
17. Buribayevich N. M., Bakhtiyorovich U. J. VENTRICULAR ARRHYTHMIAS IN HEART FAILURE IN PATIENTS WITH TYPE 2 DIABETES MELLITUS //International journal of medical sciences. – 2024. – Т. 4. – №. 05. – С. 240-248.
18. Normatov M. B., Mazhidova S. B., Abdurahimov A. A. EFFECTIVENESS OF USE OF POLYOXIDONIUM IN CHILDREN WITH COMMUNITY-ACQUIRED PNEUMONIA. – 2024.
19. Kh Y. S., Normatov M. B. Assessment of indicators of central hemodynamics in patients with chronic glomerulonephritis. – 2021.
20. Khabibovna Y. S., Buribaevich N. M. Study Of Parameters Of Central Hemodynamics In Patients With Chronic Glomerulonephritis //Достижения науки и образования. – 2020. – №. 13 (67). – С. 57-59.